Logo

Zealand Pharma Report Enrollment Completion in P-III Study of Dasiglucagon in Children with Congenital Hyperinsulinism

Share this

Zealand Pharma Report Enrollment Completion in P-III Study of Dasiglucagon in Children with Congenital Hyperinsulinism

Shots:

  • The P-III 17103 study evaluates the potential for chronic dasiglucagon infusion delivered via a pump to prevent hypoglycemia in neonates up to 12mos. old with CHI. The results of this trial are expected in Q2’22
  • The primary objective of the trial is to reduce or eliminate the need for intensive hospital treatment, reduce the frequency of dangerous low blood glucose, need for constant feeding, and to delay or eliminate the need for pancreatectomy
  • Dasiglucagon is a glucagon analog that is stable in aqueous solution and is suitable for chronic pump use and received ODD from the US FDA and EC in 2017

 Ref: Globe Newswire | Image: Zealand Pharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions